Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty

European Journal of Endocrinology

Volumn 169, Issue 2, 2013, Pages 187-201

  Plamboeck, Astrid ^a,b   Veedfald, Simon ^a   Deacon, Carolyn F ^b   Hartmann, Bolette ^b   Wettergren, Andre ^a   Svendsen, Lars B ^a   Meisner, Soren ^a   Hovendal, Claus ^c   Knop, Filip K ^a,b   Vilsboll, Tina ^a   Holst, Jens J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Capital Region   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; VILDAGLIPTIN;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DUODENUM ULCER; ESOPHAGUS CANCER; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HORMONE INHIBITION; HUMAN; HYPERGLUCAGONEMIA; INNERVATION; INSULIN RELEASE; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PYLOROPLASTY; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; TRUNCUS VAGOTOMY; VAGAL INNERVATION; VAGUS NERVE;

ACETAMINOPHEN; ADAMANTANE; AGED; AREA UNDER CURVE; CASE-CONTROL STUDIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DUODENAL ULCER; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN-SECRETING CELLS; MALE; NITRILES; PYLORUS; PYRROLIDINES; VAGOTOMY, TRUNCAL;

EID: 84880949323     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0264     Document Type: Article

References (70)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews 2007 87 1409-1439. (doi:10.1152/physrev.00034. 2006)
2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R & Zinman B. American Diabetes Association & European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 193-203. (doi:10.2337/dc08-9025)
3. Vilsbøll T, Krarup T, Madsbad S & Holst JJ. No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabetic Medicine 2001 18 144-149. (doi:10.1046/j.1464-5491.2001.00424.x)
4. Mentlein R, Gallwitz B & Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry 1993 214 829-835. (doi:10.1111/j.1432- 1033.1993. tb17986.x)
5. Hansen L, Deacon CF, Orskov C & Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999 140 5356-5363. (doi:10.1210/en.140.11.5356)
6. Deacon CF, Pridal L, Klarskov L, Olesen M & Holst JJ. Glucagonlike peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. American Journal of Physiology 1996 271 E458-E464.
7. Vilsbøll T, Agersø H, Krarup T & Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. Journal of Clinical Endocrinology and Metabolism 2003 88 220-224. (doi:10.1210/jc.2002-021053)
8. Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ & Hellstrom PM. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterology and Motility 2009 21 978-e78. (doi:10.1111/j.1365-2982. 2009.01317.x)
9. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A & Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. Journal of the Autonomic Nervous System 1996 61 149-154. (doi:10.1016/S0165-1838 (96)00071-9)
10. Balkan B & Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2000 279 R1449-R1454.
11. Ahrén B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2004 286 R269-R272. (doi:10.1152/ajpregu. 00423.2003)
12. Waget A, Cabou C, Masseboeuf M, Cattan P, Armanet M, Karaca M, Castel J, Garret C, Payros G, Maida A et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 2011 152 3018-3029. (doi:10.1210/en.2011-0286)
13. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, Nakayama K & Uchida K. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Autonomic Neuroscience 2004 110 36-43. (doi:10.1016/j.autneu. 2003. 11.001)
14. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007 148 4965-4973. (doi:10.1210/en.2006-0153)
15. Holst JJ & Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005 48 612-615. (doi:10.1007/s00125-005-1705-7)
16. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N & Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009 150 1174-1181. (doi:10.1210/en.2008-1221)
17. Humphrey CS, Dykes JR & Johnston D. Effects of truncal, selective, and highly selective vagotomy on glucose tolerance and insulin secretion in patients with duodenal ulcer. Part I-effect of vagotomy on response to oral glucose. BMJ 1975 2 112-114. (doi:10.1136/ bmj.2.5963.112)
18. Humphrey CS, Dykes JR & Johnston D. Effects of truncal, selective, and highly selective vagotomy on glucose tolerance and insulin secretion in patients with duodenal ulcer. Part II-Comparison of response to oral and intravenous glucose. BMJ 1975 19 114-116.
19. Sudo T, Ishiyama K, Takemoto M, Kawamura M, Umemura H, Shiraha S, Kuyama T, Suzuki T & Tobe T. Pancreatic endocrine function after total gastrectomy and truncal vagotomy. American Journal of Surgery 1982 144 539-544. (doi:10.1016/0002-9610(82)90576-1)
20. Hare KJ, Vilsbøll T, Holst JJ & Knop FK. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. American Journal of Physiology. Endocrinology and Metabolism 2010 298 E832-E837. (doi:10.1152/ajpendo.00700. 2009)
21. Knop FK, Vilsbøll T, Madsbad S, Holst JJ & Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007 50 797-805. (doi:10.1007/s00125-006-0566-z)
22. Kronborg O & Madsen P. Gastric emptying rate and acid secretion after truncal vagotomy and pyloroplasty for duodenal ulceration. Scandinavian Journal of Gasteroenterology 1972 7 515-518. (doi:10.3109/00365527209180948)
23. Parr NJ, Grime S, Critchley M, Baxter JN & Mackie CR. Mechanisms governing the biphasic pattern of gastric emptying after truncal vagotomy and pyloroplasty. Gut 1988 29 1253-1257. (doi:10.1136/gut.29.9.1253)
24. Pennathur A, Awais O & Luketich JD. Technique of minimally invasive Ivor Lewis esophagectomy. Annals of Thoracic Surgery 2010 89 S2159-S2162. (doi:10.1016/j.athoracsur. 2010.03.069)
25. Balaji NS, Crookes PF, Banki F, Hagen JA, Ardill JE & DeMeester TR. A safe and noninvasive test for vagal integrity revisited. Archives of Surgery 2002 137 954-958 (discussion 958-959). (doi:10.1001/ archsurg.137.8.954)
26. Willems M, Quartero AO & Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Digestive Diseases and Sciences 2001 46 2256-2262. (doi:10.1023/A:1011935603893)
27. Orskov C, Jeppesen J, Madsbad S & Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. Journal of Clinical Investigation 1991 87 415-423. (doi:10.1172/JCI115012)
28. Krarup T & Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regulatory Peptides 1984 9 35-46. (doi:10.1016/0167-0115(84) 90005-3)
29. Plamboeck A, Holst JJ, Carr RD & Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005 48 1882-1890. (doi:10.1007/s00125-005-1847-7)
30. Miceli JN, Aravind MK, Cohen SN & Done AK. Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography. Clinical Chemistry 1979 25 1002-1004.
31. Medhus AW, Lofthus CM, Bredesen J & Husebye E. Gastric emptying: The validity of the paracetamol absorption test adjusted for individual pharmacokinetics. Neurogastroenterology and Motility 2001 13 179-185. (doi:10.1046/j.1365-2982.2001. 00249.x)
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: Insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/ BF00280883)
33. Van Cauter E, Mestrez F, Sturis J & Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992 41 368-377. (doi:10.2337/diabetes. 41.3.368)
34. Hovorka R, Soons PA & Young MA. ISEC: A program to calculate insulin secretion. Computer Methods and Programs in Biomedicine 1996 50 253-264. (doi:10.1016/0169-2607(96)01755-5)
35. Jorgensen NB, Jacobsen SH, Dirksen C, Bojsen-Moller KN, Naver L, Hvolris L, Clausen TR, Wulff BS, Worm D & Lindqvist Hansen D. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. American Journal of Physiology. Endocrinology and Metabolism 2012 303 E122-E131. (doi:10.1152/ajpendo. 00073.2012)
36. Schwartz TW, Stenquist B & Olbe L. Cephalic phase of pancreaticpolypeptide secretion studied by sham feeding in man. Scandinavian Journal of Gasteroenterology 1979 14 313-320. (doi:10.3109/ 00365527909179889)
37. Jones WM & Griffith CA. On the question of vagal reinnervation of the stomach. I. The permanence of the amount of the residually innervated gastric mucosa. Annals of Surgery 1970 171 365-368. (doi:10.1097/00000658-197003000- 00007)
38. Jones WM & Griffith CA. On the question of vagal reinnervation of the stomach. II. The unchanging secretory and ulcerogenic potential. Annals of Surgery 1970 171 369-372. (doi:10.1097/ 00000658-197003000-00008)
39. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y & Ito C. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Research and Clinical Practice 2002 55 65-85. (doi:10.1016/S0168-8227(01)00365-5)
40. Humphrey CS, Dykes JR & Johnston D. Effects of truncal, selective, and highly selective vagotomy on glucose tolerance and insulin secretion in patients with duodenal ulcer. Part II-comparison of response to oral and intravenous glucose. BMJ 1975 2 114-116. (doi:10.1136/bmj.2.5963.114)
41. Hu P, Yin Q, Deckert F, Jiang J, Liu D, Kjems L, Dole WP & He YL. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. Journal of Clinical Pharmacology 2009 49 39-49. (doi:10.1177/ 0091270008325152)
42. Kraly FS, Jerome C & Smith GP. Specific postoperative syndromes after total and selective vagotomies in the rat. Appetite 1986 7 1-17. (doi:10.1016/S0195-6663(86)80038-1)
43. Kral JG. Behavioral effects of vagotomy in humans. Journal of the Autonomic Nervous System 1983 9 273-281. (doi:10.1016/0165-1838(83)90147-9)
44. Rocca AS & Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999 140 1687-1694. (doi:10.1210/en.140.4. 1687)
45. Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Worm D, Almdal T, Naver LS & Hvolris LE. Changes in gastrointestinal hormone responses, insulin sensitivity, and b-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obesity Surgery 2012 22 1084-1096. (doi:10.1007/s11695-012-0621-4)
46. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D & Nauck MA. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. Journal of Clinical Endocrinology and Metabolism 2007 92 4165-4171. (doi:10.1210/jc.2006-1932)
47. Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G & Creutzfeldt W. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: Interactions with glucose, phenylalanine, and cholecystokinin-8. Journal of Clinical Endocrinology and Metabolism 1989 69 654-662. (doi:10.1210/ jcem-69-3-654)
48. Kreymann B, Williams G, Ghatei MA & Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987 2 1300-1304. (doi:10.1016/S0140-6736(87)91194-9)
49. Vilsbøll T, Krarup T, Madsbad S & Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regulatory Peptides 2003 114 115-121. (doi:10.1016/ S0167-0115(03)00111-3)
50. Nauck MA, Bartels E, Orskov C, Ebert R & Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. Journal of Clinical Endocrinology and Metabolism 1993 76 912-917. (doi:10.1210/jc.76.4. 912)
51. Miholic J, Orskov C, Holst JJ, Kotzerke J & Meyer HJ. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Digestive Diseases and Sciences 1991 36 1361-1370. (doi:10.1007/BF01296800)
52. Lawaetz O, Blackburn AM, Bloom SR, Aritas Y & Ralphs DN. Gut hormone profile and gastric emptying in the dumping syndrome. A hypothesis concerning the pathogenesis. Scandinavian Journal of Gasteroenterology 1983 18 73-80. (doi:10.3109/0036552830 9181562)
53. Toft-Nielsen M, Madsbad S & Holst JJ. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 1998 41 1180-1186. (doi:10.1007/s00125 0051049)
54. Salehi M, Prigeon RL & D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011 60 2308-2314. (doi:10.2337/db11-0203)
55. Imeryuz N, Yegen BC, Bozkurt A, Coşkun T, Villanueva-Penacarrillo ML & Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. American Journal of Physiology 1997 273 G920-G927.
56. Hjøllund KR, Deacon CF & Holst JJ. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia 2011 54 2206-2208. (doi:10.1007/s00125-011-2168-7)
57. Fujiwara K, Gotoh K, Chiba S, Masaki T, Katsuragi I, Kakuma T & Yoshimatsu H. Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats. Journal of Neurochemistry 2012 121 66-76. (doi:10.1111/j.1471-4159.2011.07563.x)
58. Kjems LL, Holst JJ, Vølund A & Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on b-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003 52 380-386. (doi:10.2337/ diabetes.52.2.380)
59. Nauck MA, Busing M, Orskov C, Siegel EG, Talartschik J, Baartz A, Hopt UT, Becker HD & Creutzfeldt W. Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetologia 1993 30 39-45. (doi:10.1007/ BF00572873)
60. Jakob A, Largiader F & Froesch ER. Glucose turnover and insulin secretion in dogs with pancreatic allografts. Diabetologia 1970 6 441-444. (doi:10.1007/BF01212079)
61. Calhoun P, Brown KS, Krusch DA, Barido E, Farris AH, Schenk WG III, Rudolf LE, Andersen DK & Hanks JB. Evaluation of insulin secretion after pancreas autotransplantation by oral or intravenous glucose challenge. Annals of Surgery 1986 204 585-593. (doi:10.1097/00000658-198611000-00013)
62. Kohler H, Schroter-Printzen I, Nustede R, Barthel M, Ebert R & Schafmayer A. Endocrine response to intragastric and intravenous glucose challenge in the denervated dog pancreas. International Journal of Pancreatology 1992 11 117-124.
63. Nauck M, Van Hoorn W, Gubernatis G, Ebert R, Siewert JR & Creutzfeldt W. Preserved incretin effect after complete surgical denervation of the pancreas in young pigs. Research in Experimental Medicine 1985 185 291-298. (doi:10.1007/BF01851954)
64. Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B & Holst JJ. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006 130 44-54. (doi:10.1053/j.gastro.2005.10.004)
65. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T & Knop FK. Glucose-dependent insulinotropic polypeptide A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011 60 3103-3109. (doi:10.2337/db11-0979)
66. Lund A, Vilsbøll T, Bagger JI, Holst JJ & Knop FK. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. American Journal of Physiology. Endocrinology and Metabolism 2011 300 E1038-E1046. (doi:10.1152/ajpendo.00665. 2010)
67. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS & Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986 119 1467-1475. (doi:10.1210/endo-119-4-1467)
68. Meier JJ, Deacon CF, Schmidt WE, Holst JJ & Nauck MA. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 2007 50 806-813. (doi:10.1007/ s00125-007-0598-z)
69. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ & Vilsbøll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2011 96 737-745. (doi:10.1210/jc.2010-2435)
70. Holst JJ, Pedersen JH, Baldissera F & Stadil F. Circulating glucagon after total pancreatectomy in man. Diabetologia 1983 25 396-399. (doi:10.1007/BF00282517)